Literature DB >> 32766858

Exploitable metabolic dependencies in MLL-ENL-induced leukemia.

Maria-Paz Garcia-Cuellar1, Jennifer Lawlor1, Martin Böttcher2, Dimitrios Mougiakakos2, Markus Metzler3, Robert K Slany1.   

Abstract

Mixed-lineage leukemia (MLL) fusions are transcriptional activators that induce leukemia, with a dismal prognosis that mandates further elucidation of their transformation mechanism. In this study, knockdown of the direct MLL-ENL target gene polypyrimidine tract binding protein-1 (PTBP1) was rate limiting for cell proliferation and caused a metabolic phenotype associated with reduced glucose consumption and lactate production. This effect was accompanied by a reduction of splice isoform-2 of pyruvate kinase M (PKM2). Because PKM2 restricts glycolytic outflow to provide anabolic intermediates, we tested the consequences of glucose, energy, and Ser/Gly starvation for cell physiology. Administration of deoxyglucose, energetic decoupling with rotenone, and inhibition of Ser biosynthesis by CBR5884 had a significantly stronger influence on self-renewal and survival of transformed cells than on normal controls. In particular, inhibition of Ser synthesis, which branches off glycolysis caused accumulation of reactive oxygen species, DNA damage, and apoptosis, predominantly in leukemic cells. Depletion of exogenous Ser/Gly affected proliferation and self-renewal of murine and human leukemia samples, even though they are classified as nonessential amino acids. Response to Ser/Gly starvation correlated with glucose transport, but did not involve activation of the AMPK energy homeostasis system. Finally, survival times in transplantation experiments were significantly extended by feeding recipients a Ser/Gly-free diet. These results suggest selective starvation as an option for supportive leukemia treatment.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32766858      PMCID: PMC7422118          DOI: 10.1182/bloodadvances.2020001710

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  35 in total

Review 1.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.

Authors:  Mo Chen; Jian Zhang; James L Manley
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.

Authors:  Matthew G Guenther; Lee N Lawton; Tatiana Rozovskaia; Garrett M Frampton; Stuart S Levine; Thomas L Volkert; Carlo M Croce; Tatsuya Nakamura; Eli Canaani; Richard A Young
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

Review 3.  The molecular mechanics of mixed lineage leukemia.

Authors:  R K Slany
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

4.  Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Authors:  C Dafflon; V J Craig; H Méreau; J Gräsel; B Schacher Engstler; G Hoffman; F Nigsch; S Gaulis; L Barys; M Ito; J Aguadé-Gorgorió; B Bornhauser; J-P Bourquin; A Proske; C Stork-Fux; M Murakami; W R Sellers; F Hofmann; J Schwaller; R Tiedt
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

Review 5.  Serine, glycine and one-carbon units: cancer metabolism in full circle.

Authors:  Jason W Locasale
Journal:  Nat Rev Cancer       Date:  2013-07-04       Impact factor: 60.716

6.  Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage.

Authors:  Dmitri Wiederschain; Hidehiko Kawai; Ali Shilatifard; Zhi-Min Yuan
Journal:  J Biol Chem       Date:  2005-04-25       Impact factor: 5.157

7.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

Authors:  Charles J David; Mo Chen; Marcela Assanah; Peter Canoll; James L Manley
Journal:  Nature       Date:  2009-12-13       Impact factor: 49.962

8.  Serine is a natural ligand and allosteric activator of pyruvate kinase M2.

Authors:  Barbara Chaneton; Petra Hillmann; Liang Zheng; Agnès C L Martin; Oliver D K Maddocks; Achuthanunni Chokkathukalam; Joseph E Coyle; Andris Jankevics; Finn P Holding; Karen H Vousden; Christian Frezza; Marc O'Reilly; Eyal Gottlieb
Journal:  Nature       Date:  2012-10-14       Impact factor: 49.962

9.  RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.

Authors:  Adam C Wilkinson; Erica Ballabio; Huimin Geng; Phillip North; Marta Tapia; Jon Kerry; Debabrata Biswas; Robert G Roeder; C David Allis; Ari Melnick; Marella F T R de Bruijn; Thomas A Milne
Journal:  Cell Rep       Date:  2013-01-24       Impact factor: 9.423

10.  D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization.

Authors:  Martin Böttcher; Kathrin Renner; Raffaela Berger; Kristin Mentz; Simone Thomas; Zugey Elizabeth Cardenas-Conejo; Katja Dettmer; Peter J Oefner; Andreas Mackensen; Marina Kreutz; Dimitrios Mougiakakos
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.